Specific therapies for human papilloma virus infections

Current Opinion in Infectious Diseases

Volumn 11, Issue 6, 1998, Pages 733-737

  Snoeck, R ^a   Andrei, G ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CIDOFOVIR; IMIQUIMOD; IMMUNOMODULATING AGENT; VIRUS VACCINE;

CELL CYCLE; CELL INTERACTION; CELL PROLIFERATION; EPITHELIUM CELL; HOST CELL; HUMAN; IMMUNE STATUS; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; RECURRENT DISEASE; REVIEW; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS;

EID: 0032420496     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199812000-00014     Document Type: Review

References (53)

1. Phelps WC, Barnes JA, Lobe DC. Molecular targets for human papillomaviruses: prospects for antiviral therapy. Antiviral Chem Chemother 1998; 9:359-377. This paper dearly reviews the potential targets for anti-HPV therapies, clarifying the interaction between virus and the host cell replicating cycle.
2. Alani RM, Münger K. Human papillomaviruses and associated malignancies. J Clin Oncol 1998; 16:330-337. A paper focusing on the relationship between HPV and cancer, with comments on their treatment and prevention, particularly vaccination.
3. Kalantari M, Karlsen F, Johansson B, Sigurjonsson T, Wärleby B, Hagmar B. Human papillomavirus finding in relation to cervical intraepithelial neoplasia grade: a study on 476 Stockholm women, using PCR for detection and typing of HPV. Hum Pathol 1997; 28:899-1229.
4. Elkas J, Farias-Eisner R. Cancer of the uterine cervix. Curr Opin Obstet Gynecol 1998; 10:47-50.
5. Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998; 51:96-103.
6. Krüger-Kjaer S, van den Brule AJC, Svare El, Engholm G, Sherman ME, Poll PA et al. Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. Int J Cancer 1998; 76:613-619.
7. Feldman JG, Chirgwin K, Dehovitz JA, Minkoff H. The association of smoking and risk of condyloma acuminatum in women. Obstet Gynecol 1997; 89:346-350.
8. Olaitan A, Mocroft A, McCarthy K, Phillips A, Reid W, Johnson M. Cervical abnormality and sexually transmitted disease screening in human immunodeficiency virus-positive women. Obstet Gynecol 1997; 89:71-75.
9. Chiasson MA, Ellerbrock TV, Bush TJ, Sun X-W, Wright TC. Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus. Obstet Gynecol 1997; 89:690-694.
10. Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst 1998; 23:43-49.
11. Euvrard S, Kanitakis J, Chardonnet Y, Pouteil Noble C, Touraine JL, Faure M et al. External anogenital lesions in organ transplant recipients. Arch Dermatol 1997; 133:175-178.
12. Shamanin V, zur Hausen H, Lavergne D, Proby CM, Leigh IM, Neumann C et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996; 88:802-811.
13. Beutner KR, Ferenczy A. Therapeutic approaches to genital warts. Am J Med 1997; 102:28-37. Genital warts are one of the most common presentations of HPV infection and their treatment is well described in this paper.
14. Baker GE, Tyring SK. Therapeutic approaches to papillomavirus infections. Infect Dis Dermatol 1997; 15:331-340. A clear summary of the present status of HPV-induced lesion therapy.
15. Gross G. Therapy of human papillomavirus infection and associated epithelial tumors. Intervirology 1997; 40:368-377. A paper reviewing the last therapeutical modalities with special focus on interferon treatments.
16. Stellato G, Nieminen P, Aho M, Lehtinen T, Paavonen J. Type 1 cytokine response and treatment outcome of genital HPV lesions. Genitourin Med 1997; 73:387-390.
17. Johnson PJ, Mirzai TH, Bentz ML. Carbon dioxide laser ablation of anogenital condyloma acuminata in pediatric patients. Ann Plast Surg 1997; 39:578-582.
18. Davila GW, Shroyer KR. Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection. Gynecol Obstet Invest 1996; 41:275-277.
19. Swinehart JM, Skinner RB, McCarty JM, Miller BH, Tyring SK, Korey A, Orenberg EK. Development of intralesional therapy with fluorouracil/ adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies. Genitourin Med 1997; 73:481-487.
20. Giuliano AR, Gapstur S. Can cervical dysplasia and cancer be prevented with nutrients? Nutrition Rev 1998; 56:9-16.
21. Narayanan BA, Holladay EB, Nixon DW, Mauro CT. The effect of all-trans and 9-cis retinoic acid on the steady state level of HPV 16 E6/E7 mRNA and cell cycle in cervical carcinoma cells. Life Sci 1998; 63:566-573.
22. Bonnez W, Oakes D, Bailey-Farchione A, Choi A, Hallahan D, Corey L et al. A randomized, double-blind trial of parenteral low dose versus high dose interferon-β in combination with cryotherapy for treatment of condyloma acuminatum. Antiviral Res 1997; 35:41-52.
23. Strand A, Wilander E, Zehbe I, Rylander E. High risk HPV persists after treatment of genital papillomavirus infection but not after treatment of cervical intraepithelial neoplasia. Acta Obstet Gynecol Scand 1997; 76:140-144.
24. Martin-Hirsch PL, Whitehurst C, Buckley CY, Moore JV, Kitchener HC. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Lancet 1998; 351:1403.
25. Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998; 108:962-967.
26. Tyring S, Edwards L, Ramsdell CLK, Kotner S, Greenberg MD, Vance JC et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998; 134:33-38.
27. Ward KA, Armstrong KD, Maw RD, Winther MD, Gilburt SJ, Dinsmore WW. A pilot study to investigate the treatment of anogenital warts with topical lithium succinate cream (8% lithium succinate, 0.05% zinc sulphate). Int J STD AIDS 1997; 8:515-517.
28. Yuan F, Liu K, Sepkovic D, Bradlow HL, Auborn KJ. Interplay between HPV 16 and estrogen metabolism: modulation with indole-3-carbinol. In: The 1998 Molecular Biology of Small DNA Tumour Viruses Meeting, University of Wisconsin, Madison, WI, 14-19 July 1998 [abstract]; 1998. p. 161.
29. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1998; 118:810-815.
30. Glass AT, Solomon BA. Cimetidine therapy for recalcitrant warts in adults. Arch Dermatol 1996; 132:680-682.
31. Wargon O. Cimetidine for mucosal warts in an HIV positive adult. Aust J Dermatol 1996; 37:149-150.
32. Yilmaz E, Alpsoy E, Basaran E. Cimetidine therapy for warts: a placebo-controlled, double-blind study. J Am Acad Dermatol 1996; 34:1005-1007.
33. Saenz-Santamaria MC, Gilaberte Y. Cimetidine and warts. Arch Dermatol 1997; 133:530-531.
34. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134:25-30.
35. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas Jr JM. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230-239.
36. Beutner KR, Tyring SK, Trofatter Jr KF, Douglas Jr JM, Spruance S, Owens ML et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42:789-794.
37. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178:551-555.
38. Syed TA, Ahmadpour OA, Ahmad SA, Ahmad SH. Management of female genital warts with an analog of imiquimod 2% in a cream: a randomized, double-blind, placebo-controlled study. J Dermatol 1998; 25:429-433.
39. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997; 8:1-23.
40. Safrin S, Cherrington J, Jaffe HS. Clinical uses of cidofovir. Rev Med Virol 1997; 7:145-156.
41. Snoeck R, Arens M, Muller C, Noel JC, De Clercq E, Bossens M. Preliminary results on the activity of cidofovir for the treatment of cervical intraepithelial neoplasia (CIN) grade III [abstract 108]. Antiviral Res 1997; 34:A72.
42. Snoeck R, Bossens M, Parent D, Delaere B, De Greef H, De Clercq E , et al. A double-blind, placebo-controlled study of cidofovir gel for human papillomavirus (HPV)-associated genital warts [Abstract 27]. Antiviral Res 1998; 37:A47.
43. Douglas J, Schacker T, Tyring S, Kriesel J, Bowden B, Crosbyn D, et al. A phase I/II study of cidofovir topical gel for refractory anogenital condyloma acuminatum in patients with HIV infection. In: 55th Annual Meeting of the American Association of Dermatology, San Francisco, 21-26 March [abstract]; 1997.
44. Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clercq E, Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J Med Virol 1998; 54:219-225.
45. Snoeck R, Andrei G, Piette J, De Clercq E. Antiproliferative potential of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with various HPV-negative cell lines. In: Abstracts of the 37th ICAAC, Toronto, Canada, 28 September-1 October [abstract 159]; 1997.
46. Andrei G, Snoeck R, Schols D, De Clercq E. Human papillomavirus (HPV)-positive cells undergo apoptosis following exposure to cidofovir. In: The 1998 Molecular Biology of Small DNA Tumour Viruses Meeting, University of Wisconsin Madison, WI, 14-19 July [abstract]; 1998 p. 175.
47. Andrei G, Snoeck R, Piette J, De Clercq E. Cidofovir: induction of apoptosis in human papillomavirus (HPV)-containing cell lines. In: The Tenth International Conference on Antiviral Research, Atlanta, Georgia, 6-11 April [abstract]; 1997 p. 107.
48. Hines JF, Ghim S-J, Jenson AB. Prospects for human papillomavirus vaccine development: emerging HPV vaccines. Curr Opin Obstet Gynecol 1998; 10:15-19.
49. McNeil C. HPV vaccine treatment trials proliferate, diversify. J Natl Cancer Inst 1997; 89:280-281.
50. McNeil C. HPV vaccines for cervical cancer move toward clinic, encounter social issues. J Natl Cancer Inst 1997; 89:1664-1666.
51. Galloway DA. Is vaccination against human papillomavirus a possibility? Lancet 1996; 351 (Suppl III):22-24.
52. Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, Penalver M, Averette HE. In vitro antigene therapy targeting HPV 16 E6 and E7 in cervical carcinoma. Gynecol Oncol 1997; 64:18-25.
53. Hamada K, Sakaue M, Alemany R, Zhang WW, Horio Y, Roth JA, Mitchell MF. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 1996; 63:219-227.